2Heys SD, Ogston K, Miller I ,et al.Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: results of a randomized controlled trial[J]. Oncol,1998,12(1):221 -225.
3Fishher ER, Wang J, Bryant J, et al.Pathobioloqy of preoperative chemotherapy: findings form the National Surgical Adjuvant Breast and Bowel(NSABP)B- 18[J]. Cancer, 2002, 95(4):681 - 695.
4Macgrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma :Predictive value of the immunohistoehemical detection of hormonal receptors,p53, c-erbB-2,MiB1, pS2 and GSTII[J]. Br J Cancer, 1996,74: 1458-1465.
5Ogston KN,Miller ID,Schofield AC,et al.Can patients likelihood of benefiting from primary chemotherapy for breast ancer be predicted before commencement of treatment[J].Breast Vancer Res Treat,2004 86:181-189.
6Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer[J]. Eur J Cancer, 1999, 35: 574-579.
7Makris A, Powles T J, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas [J].Clin Cancer Res, 1997,3:593 -600.
8Penault-Llorca F, Cavre A,Bouchet Mishellany F, et al.Induction chemotherapy for breast carcinoma:predictive markers and relation with outcome[J].Int J Oncol,2003,22(6): 1319- 1325.
9Gregory RK, Powle TJ, Salter J,et al. Prognostic relevance of cerbB-2 expression following neoadjuvant chemotherapy in patients in a randomized trial of neoadjuvant versus adjuvant chemoendocrine therapy[J].Breast Cancer Res Treat,2000,59(2): 171-175.
10Zhang F, Yang Y, Smith T,et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5- fluorouracil, doxorubicin. And cyclophosphamide in patients with breast carcinoma[J]. Cancer. 2003, 97(7): 1758-1765.
